Sparks commentary - Herantis Pharma

Healthcare

Sparks - Herantis Pharma

More on this equity
Herantis Pharma (HEL: HRTIS) appoints new chief medical officer
Published by Arron Aatkar, PhD

Herantis Pharma has announced the appointment Dr Juha Savola, MD, PhD as chief medical officer (CMO). Juha brings over 25 years of global drug development, regulatory and executive leadership experience spanning neurology, gene therapy and rare diseases. Throughout his career, he has helped shape development strategies for innovative therapies from early clinical development through to regulatory approval and commercialisation, with extensive expertise in clinical and regulatory strategy, health authority engagement, programme acceleration and strategic partnering. The appointment of Juha as CMO is intended to support the development of HER-096, as the company evaluates strategic partnering opportunities and works to bring this potential disease-modifier to Parkinson’s disease patients.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.